Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2017

View Archived Issues

VEROnA trial explores use of vandetanib-eluting radiopaque beads for liver cancer

Iterum Therapeutics conducts phase I study of sulopenem etzadroxil

OncoArendi Therapeutics set to begin clinical studies of lead compound for asthma

Trovagene's PCM-075 granted orphan drug status in U.S.

Hyundai Pharmaceutical describes diabetes candidate HD-6277

Novel mutation in NSD1 gene found to be associated with Sotos syndrome

Compugen reports data demonstrating potential of CGEN-15032 as a target for cancer therapy

International Stem Cell develops 3-D bioprinter to treat liver diseases

Kyowa Hakko Kirin discontinues development of ARQ-197

FDA accepts for review Prolia sBLA for glucocorticoid-induced osteoporosis

sNDA submitted for rucaparib as maintenance treatment in platinum-sensitive recurrent ovarian cancer

NIA grant supports Amydis' development of ophthalmic amyloid test for CAA

Erytech resubmits Graspa MAA to EMA

Nicox and pSivida collaborate to develop sustained-release NO-donating ocular compound

Volanesorsen granted PIM designation for familial chylomicronemia syndrome

Bayer presents Pim kinase inhibitors

New integrin antagonists presented by GlaxoSmithKline

Centaurus BioPharma and collaborators divulge novel CDK inhibitors

DGMIF and Gachon University patent FGFR inhibitors

Novel Ret inhibitors presented by Blueprint Medicines

Mundipharma EDO initiates phase I/II study of tinostamustine in advanced solid tumors

RBX-2660 microbe therapy prevents recurrent Clostridium difficile infection in phase II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...